S
Shanghai Xunyao Biotechnology
A cutting-edge medication development company focused on coagulation and fibrosis
About Shanghai Xunyao Biotechnology
Established in 2021, Shanghai Xunyao Biotechnology Co., Ltd. (also known as Synvida-Bio) is a biopharmaceutical company that emerged from a strategic, mixed-ownership collaboration. The company was founded by Professor Junling Liu and his research group from the School of Medicine at Shanghai Jiao Tong University, in partnership with Shanghai Pharmaceuticals Holding Co., Ltd. This structure combines academic research with industrial and capital resources, aiming to accelerate drug development.
The firm's core business is the research and development of innovative therapeutics for unmet clinical needs, with a particular focus on blood-related disorders. Its technology platform, which integrates synthetic biology with AI, is dedicated to the discovery and modification of antibody and protein drugs. The company's pipeline targets a range of diseases including hemophilia, thrombocytopenia, pulmonary fibrosis, and various thrombotic diseases. Beyond this, Synvida-Bio is also engaged in developing nucleic acid therapies and cell-based treatments for a broader spectrum of therapeutic areas such as neoplasms, nervous system diseases, and immune system disorders.
Synvida-Bio operates on a model that involves advancing its own drug pipeline and potentially out-licensing its developments to larger pharmaceutical partners for late-stage clinical trials and commercialization. The company's pipeline includes several drug candidates, such as a recombinant humanized anti-PEAR1 monoclonal antibody, with some projects having reached the pre-IND application stage and clinical trials. The company secured $28.1 million in a Series A venture capital round in January 2024, with investors including Lapam Capital and Shanghai Healthcare Capital, to fund its ongoing research and development activities.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 52.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- SaaS
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2024 | $28M | $110M | SHC Shanghai Biomedical Fund · Longpan Investment | ↗ |
Growth signals
Latest recorded traffic for Shanghai Xunyao Biotechnology is 200 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Xunyao Biotechnology in its local ecosystem
The Shanghai Xunyao Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- LILongpan Investment
SHC Shanghai Biomedical Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Xunyao Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Xunyao Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








